Payment overview · 2025
General Payments
$7,387.80
5 reported records · 1 companies
Healthcare provider profile · identity verified
Brian David Hess, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BILLINGS, MT · NPI 1124514609
Verified facts
What the public records show
CMS Open Payments records show Brian David Hess, MD received $7,387.80 in general payments during 2025 across 5 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 100.0% of that reported general-payment amount.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $7,387.80 | 100.0% | 5 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,460.00 | 1 |
| Consulting Fee | $910.00 | 2 |
| Travel and Lodging | $895.81 | 1 |
| Food and Beverage | $121.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
145 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 559 | 170 |
| Lisinopril | Lisinopril | 398 | 132 |
| Omeprazole | Omeprazole | 344 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 337 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 294 | 100 |
| Losartan Potassium | Losartan Potassium | 290 | 101 |
| Metoprolol Succinate | Metoprolol Succinate | 222 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 208 | 66 |
| Metformin Hcl | Metformin Hcl | 183 | 56 |
| Simvastatin | Simvastatin | 183 | 61 |
| Furosemide | Furosemide | 175 | 50 |
| Potassium Chloride | Potassium Chloride | 168 | 48 |
| Gabapentin | Gabapentin | 164 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 161 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 154 | 56 |
| Eliquis | Apixaban | 145 | 30 |
| Trazodone Hcl | Trazodone Hcl | 145 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 143 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 141 | 27 |
| Ozempic | Semaglutide | 139 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 131 | 45 |
| Oxycodone Hcl | Oxycodone Hcl | 118 | 23 |
| Tramadol Hcl | Tramadol Hcl | 112 | 34 |
| Sertraline Hcl | Sertraline Hcl | 108 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 101 | 32 |
| Metformin Hcl Er | Metformin Hcl | 99 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 97 | 25 |
| Allopurinol | Allopurinol | 92 | 32 |
| Warfarin Sodium | Warfarin Sodium | 92 | 28 |
| Jardiance | Empagliflozin | 88 | 23 |
| Meloxicam | Meloxicam | 87 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 84 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 22 |
| Famotidine | Famotidine | 78 | 18 |
| Carvedilol | Carvedilol | 76 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 28 |
| Pregabalin | Pregabalin | 63 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 18 |
| Trulicity | Dulaglutide | 58 | 13 |
| Finasteride | Finasteride | 53 | 18 |
| Bupropion Xl | Bupropion Hcl | 50 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 14 |
| Januvia | Sitagliptin Phosphate | 50 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 49 | 49 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 13 |
| Lorazepam | Lorazepam | 47 | 13 |
| Spironolactone | Spironolactone | 47 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 18 |
| Atenolol | Atenolol | 43 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | 12 |
| Celecoxib | Celecoxib | 42 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 41 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 41 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 40 | suppressed |
| Clonazepam | Clonazepam | 39 | 11 |
| Donepezil Hcl | Donepezil Hcl | 39 | suppressed |
| Glipizide Er | Glipizide | 39 | 14 |
| Premarin | Estrogens, Conjugated | 39 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 33 | 13 |
| Estradiol | Estradiol | 33 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Alprazolam | Alprazolam | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 32 | 26 |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | 13 |
| Morphine Sulfate | Morphine Sulfate | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 15 |
| Lactulose | Lactulose | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | 11 |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 22 | suppressed |
| Prednisone | Prednisone | 22 | 14 |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Nyamyc | Nystatin | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 14 |
| Baclofen | Baclofen | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Indomethacin | Indomethacin | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 14 |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Victoza 3-Pak | Liraglutide | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $7,387.80 · 5 records | E.R. Squibb & Sons, L.L.C. | — | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error